Bempedoic Acid

證據等級: L5

預測適應症: 10 個

Bempedoic Acid: From LDL-Cholesterol Lowering to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Bempedoic acid is an ATP-citrate lyase (ACL) inhibitor used to lower LDL-cholesterol in patients with hypercholesterolemia and elevated cardiovascular risk. Among the TxGNN model's top 10 predictions, most (hyperthyroidism, veterinary infections, oncogenic syndromes, etc.) show no plausible mechanistic link and are annotated as likely knowledge-graph noise. The one prediction with genuine biological rationale and real-world evidence is Homozygous Familial Hypercholesterolemia (HoFH), supported by 1 real-world cohort study and 17 additional publications, though no clinical trials are currently registered for this specific population.

Quick Overview

Item	Content
Original Indication	Not captured in structured data (`original_indications` empty). Based on mechanistic evidence in this pack, bempedoic acid is used for LDL-C lowering / primary hypercholesterolemia
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.48% (rank 6040 of the disease space)
Evidence Level	L3 (real-world cohort + review literature, no RCTs)
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Note on ranking: TxGNN's #1-ranked prediction (hyperthyroidism, score 99.61%) and most other top-10 predictions were excluded from this report — the evidence pack itself flags them as having "no plausible mechanism" or being mismatched to unrelated drugs (e.g., tiratricol) or veterinary diseases. This report focuses on rank 6 (HoFH), the only candidate with a coherent mechanism and supporting literature.

Why is This Prediction Reasonable?

Currently, a structured mechanism-of-action (MOA) record for bempedoic acid is not available in this evidence pack (original_moa: [Data Gap]). However, the repurposing rationale attached to the HoFH prediction provides sufficient mechanistic detail to evaluate plausibility.

Bempedoic acid is an ATP-citrate lyase (ACL) inhibitor that acts upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. It is a prodrug activated selectively in the liver (via VLACS1, an enzyme not expressed in skeletal muscle), which explains its favorable muscle-related side-effect profile compared to statins. This liver-selective inhibition upregulates LDL receptor (LDLR) expression, thereby lowering circulating LDL-C.

HoFH patients most commonly carry compound heterozygous or homozygous LDLR mutations that reduce — but do not always completely abolish — receptor function. Because bempedoic acid's mechanism depends on residual LDLR activity, patients with non-null LDLR genotypes may retain partial pharmacological response. This makes bempedoic acid mechanistically plausible as an add-on therapy for HoFH patients who remain above LDL-C targets despite statins and PCSK9 inhibitors, rather than as a monotherapy or first-line treatment.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41274797	2026	Real-world cohort	J Clin Lipidol	Direct real-world evaluation of bempedoic acid efficacy and tolerability specifically in HoFH patients
41741298	2026	Expert consensus	J Clin Lipidol	National Lipid Association update on FH management, reflecting current LDL-C lowering strategies including bempedoic acid
35466160	2022	Review	J Atheroscler Thromb	Reviews treatment advancements for HoFH, positioning bempedoic acid among add-on LDL-C lowering options
41106315	2025	Review	Exp Mol Pathol	Innovative therapies for HoFH management, covering LDLR-targeted and adjunct pharmacotherapies
41694628	2026	Case report + review	Clin Case Rep	Case of catastrophic HoFH progression after interrupted follow-up; underscores need for continuous aggressive LDL-C control
29449335	2018	Preclinical	Arterioscler Thromb Vasc Biol	Bempedoic acid lowers LDL-C and attenuates atherosclerosis in LDLR-deficient (LDLR+/- and LDLR-/-) miniature pig model, directly relevant to HoFH pathophysiology
37071085	2024	Review (comparator drug)	Cardiol Rev	Discusses evinacumab for HoFH, referencing bempedoic acid among adjunct lipid-lowering therapies
33766264	2021	Review	J Am Coll Cardiol	JACC seminar on emerging LDL-C/ApoB-lowering therapies, discusses bempedoic acid's mechanism and clinical role
35754818	2022	Review	Front Genet	Reviews treatment progression for refractory hypercholesterolemia including HoFH
34081216	2021	Review	Curr Cardiol Rep	Reviews management updates beyond statins/PCSK9i for familial and refractory hypercholesterolemia

Germany Market Information

Bempedoic acid is currently not marketed in Germany under this evidence pack (market_status: 未上市, total_licenses: 0); no authorization records are available.

Safety Considerations

Structured safety data for this drug is currently a blocking data gap (DG001, severity: Blocking) — TFDA/regulatory label warnings and contraindications have not yet been retrieved, and DDI screening returned no results (query_status: not_found). This gap must be resolved before the candidate can advance past initial safety screening (S1).

Please refer to the package insert for safety information once available.

Conclusion and Next Steps

Decision: Proceed with Guardrails (for the HoFH indication specifically; all other TxGNN top-10 predictions for this drug are Hold due to absent mechanistic rationale and no supporting evidence)

Rationale: Bempedoic acid's liver-selective, LDLR-dependent mechanism is biologically compatible with HoFH as an adjunct therapy, and this is supported by one real-world cohort study plus consistent review-level literature — but no dedicated randomized controlled trial exists in this population, capping the evidence at L3.

To proceed, the following is needed:

Resolve blocking data gap DG001: obtain TFDA/regulatory label warnings and contraindications before any S1 safety evaluation
Obtain drug-drug interaction (DDI) data (current query returned no results)
Confirm structured mechanism-of-action data via DrugBank API (DG002)
Seek prospective or controlled trial data in HoFH populations (currently only real-world/observational evidence exists)
Given the drug is not currently marketed in Germany, clarify regulatory pathway/import status before pursuing local development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.